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i.org/1patients who underwent transcatheter aortic valve implantation with contrasting data
about efficacy and safety. Pubmed, Medline, and Google Scholar were systematically
searched for studies of these different devices, with data derived from randomized
controlled trial or registries with multivariate analysis. All-cause death at 30 days and at
follow-up were the primary end points, whereas postprocedural moderate or severe aortic
regurgitation (AR), stroke, major vascular complications, bleedings, and pacemaker im-
plantation the secondary ones. Six studies with 957 self-expanding and 947 balloon-
expandable valves were included: 1 randomized controlled trial and 5 observational
studies. At 30 days follow-up, rates of death did not differ between self-expanding and
balloon-expandable valves (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17),
whereas balloon expandable reduced rates of moderate or severe AR (OR 0.51, 95% CI 0.27
to 0.99) and of pacemaker implantation (OR 0.28, 95% CI 0.17 to 0.47). After a follow-up of
360 days (300 to 390), rates of all-cause death did not differ between the 2 groups. In
conclusion, risks of moderate or severe AR and pacemaker implantation were lower with
the balloon-expandable devices without an impact on 30 days and midterm mortal-
ity.  2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;115:1720e1725)Transcatheter aortic valve implantation (TAVI) now rep-
resents an effective strategy for patients with severe aortic
stenosis at high risk for surgery, as demonstrated by ran-
domized controlled trials1,2 and large observational studies.3
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0.1016/j.amjcard.2015.03.015excellent results in terms of clinical outcomes.7 Although
self-expanding devices expose patients to more frequent
pacemaker implantations, with increased costs but without a
negative impact on prognosis,8 contrasting data have been
reported about postimplant aortic regurgitation (AR), one
of the most common complications of TAVI, with a well-
defined impact on prognosis.9 Recently, some registries
have demonstrated an increased risk of AR for patients
treated with self-expanding devices10,11 as subsequently
confirmed by a single randomized controlled trial.12These
studies, however, are limited by small sample size, not
allowing conclusive appraisal about the most efficacious and
safe device for patients with TAVI. Consequently, we per-
formed a meta-analysis of randomized controlled trials and
adjusted observational studies to compare self-expanding
and balloon-expandable devices.Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) amendment to the Quality of
Reporting of Meta-analyses statement and recommendations
from the Cochrane Collaboration and Meta-analysis of
Observational Studies in Epidemiology were followed dur-
ing the development of the present systematic review.13e15www.ajconline.org
Figure 1. Flow chart.
Valvular Heart Disease/Basic Features of Included Studies 1721Pertinent articles were searched for in Medline, Cochrane
Library, Biomed Central, and Google Scholar without time
limit (up to June 4, 2014) in keeping with established
methods with Medical Subject Headings (MeSH) strategy
and with the following terms, including “TAVI” or “trans-
catheter aortic valve implantation” or “self-expandable” or
“balloon expandable” or “Corevalve” or “Edwards.”
Two independent reviewers (FDA and GBZ) screened
the retrieved citations through the title and/or abstract, and
divergences were resolved through consensus. If potentially
pertinent, studies were then appraised as complete reports
according to the following explicit selection criteria. Studies
were included if (i) they reported outcomes of patients with
TAVI treated with self-expanding or balloon-expandable
techniques and (ii) randomized controlled trials or obser-
vational studies adjusted with multivariate analysis, whereas
exclusion criteria were (i) nonhuman setting and (ii) dupli-
cate reporting (in which case the manuscript reporting the
largest sample of patients was selected).
Two independent reviewers (FDA and GBZ) abstracted
the following data on prespecified forms: authors, journal,
year of publication, location of the study group, and baseline
clinical and interventional features. Data extraction was
conducted by mutual agreement, and all potential dis-
agreements were resolved by consensus. All-cause death at
30 days and at follow-up were the primary end points,
whereas postprocedure moderate or severe AR, stroke,
major vascular complications and bleedings, and pacemaker
the secondary ones.
Continuous variables are reported as mean (SD) or me-
dian (interquartile). Categorical variables are expressed as n/
N (%). Statistical pooling was performed according to a
random-effect model with generic inverse-variance weight-
ing, computing risk estimates with 95% confidence in-
tervals, using RevMan 5 (The Cochrane Collaboration, The
Nordic Cochrane Centre, Copenhagen, Denmark). Pairwise
meta-analysis was performed for overall studies, whereas
meta-regression analysis was performed to test the effect of
baseline features on primary and secondary outcomes. The
study was approved by an institutional review committee
and that the subjects gave informed consent.Results
After literature search, 8 full texts were evaluated for
inclusion into review: 2 were excluded as they did not report
on outcomes adjusted through multivariate analysis16,17 and
finally 6 studies were included7,10e12,18,19 (Figure 1).
All the studies were multicenter, with a single random-
ized controlled trial, all of them exploiting balloon-
expandable devices of 23 and 26 mm and self-expanding
devices of 23, 26, 29, and 31 mm (Tables 1 and 2).
Overall, 957 self-expandable and 947 balloon-
expandable valves were included, with a median age of 82
(81 to 83) years, 42% (36 to 53) of them being women, with
a median logistic EuroSCORE of 22 (21 to 22). Median
annulus diameter was 22 mm (21 to 23); 26-mm devices
were implanted in 50% (44 to 51) of the patients, 23 mm in
15% (4 to 18), 29 mm in 33% (31 to 37), and 31 mm in 2%
(1 to 2) (Table 3).
At 30 days follow-up, rates of death did not differ be-
tween self-expanding and balloon-expandable valves (odds
ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17),
whereas balloon expandable reduced rates of moderate or
severe AR (OR 0.51, 95% CI 0.27 to 0.99) and of pace-
maker implantation (OR 0.28, 95% CI 0.17 to 0.47). Both
valves performed similar for major and life-threatening
bleedings (24% [16 to 32] vs 27% [20 to 34]; OR 1.40,
95% CI 1.18 to 1.66) and for major vascular complications
(6% [3 to 9] vs 9% [5 to 13]; OR 1.17, 95% CI 0.81 to 1.69).
After a follow-up of 360 days (300 to 390), rates of all-
cause death did not differ between the 2 groups (15% [11 to
16] vs 13% [12 to 17]; OR 0.95, 95% CI 0.60 to 1.51). At
meta-regression analysis, benefit of balloon-expandable
valves to reduce AR increased with annulus diameter
(beta 0.15, p <0.001; see Figures 2 to 7), whereas other
clinical variables were not significantly related to primary
and secondary end points.
Discussion
To the best of our knowledge, this is the largest study
comparing balloon-expandable and self-expanding devices
for patients with TAVI, demonstrating that (a) balloon-
expandable prosthesis reduced the rates of moderate and
severe AR and of pacemaker implantation; and (b) rates of
30 and 360 days death did not vary.
AR represents one of the most common complications
for patients with TAVI.20e22 Balloon-expandable valves
reduced risk of AR compared with self-expanding valves, in
studies exploiting second and third generations of currently
available devices.
Our results confirmed in a larger population those derived
from the only randomized controlled trial on the topic
included in the present analysis.12 Many different explana-
tions have been provided. Burden of aortic calcification may
play a crucial role because it may reduce the complete sealing
of the paravalvular space. This may be particularly relevant
for self-expanding valves, which were recently demonstrated
to be inferior regarding radial force,23 especially for patients
with a large angle between ascending aorta and left ventricle
outflow tract because of their longer size.24 Similarly, the
results of the meta-regression analysis demonstrated an
increased superiority for balloon-expandable devices in
Table 1
Baseline features of included studies
Include
reference
Design of the
study
Number of
centers
Region Years of
enrollement
Abdel-Wahab, 201410 Observational, prospective 2 Europe 2007-2012
Chieffo, 20137 Observational, prospective 3 Europe 2011
Choice, 201412 Randomized controlled 8 Europe 2012-2013
Nombela-Franco, 201311 Observational, prospective 4 North America 2012-2013
D0Ascenzo, 201318 Observational, prospective 5 Europe 2008-2012
Watanabe, 201319 Observational prospective 2 Europe 2008-2012
Table 2
Devices used
Study Kind of balloon expandable
devices
Kind of self expandable
devices
Abdel-Wahab, 2014 Edwards SAPIEN XT 23/26 mm
Delivery system of 18/19 F
Medtronic Core Valve 26/29 mm
Delivery system of 18 F
Chieffo, 2013 Edwards SAPIEN/ Edwards SAPIEN XT 23/26 mm
Delivery system of 18/19/22/24 F
Medtronic Core Valve 26/29 mm
Delivery system of 18 F/21 F
Choice, 2014 Edwards SAPIEN XT 23/26/29 mm
Delivery system of 16-20 F
Medtronic Core Valve 23/26/29/31 mm
Delivery system of 18 F
Nombela-Franco, 2013 Edwards SAPIEN XT 26 mm Medtronic Core Valve 26 mm
D0Ascenzo, 2013 Edwards SAPIEN/ Edwards SAPIEN XT 23/26/29 mm
Delivery system of 19/22/24 F
Medtronic Core Valve 26/29/31 mm
Delivery system of 18 F/21 F
Watanabe, 2013 Edwards SAPIEN 23/26 mm
Delivery system of 19/22 F
Medtronic Core Valve 26/29 mm
Delivery system of 18 F
Table 3
Baseline and interventional features of patients (all data are reported as
percentages or median with first and third quartiles)
6 studies, 1903 patients
Age (years):mean(range) 82 (81-83)
women 42% (36%-53%)
Diabetes Mellitus 28% (27%-29%)
Previous myocardial infarction 12% (11%-17%)
Ejection fraction less than 35% 14.5 %(14%-17%)
Severe renal disease 16% (11%-39%)
Logistic Euroscore 22 (21-22)
STS score 8 (7.5-8.5)
Annulus (mm) 22 (21-23)
Prosthesis diameter (mm)
23 15 %(4%-18%)
26 50%(44%-51%)
29 33%(31%-37%)
31 2 %(1%-2%)
Figure 2. Ratesof inhospital complications—all-causedeathat30daysandat
follow-upinballoon-expandableandself-expandablevalves.PM¼pacemaker
implantation.
1722 The American Journal of Cardiology (www.ajconline.org)larger diameters, probably related to similar reasons. It
should be remembered, however, that AR remains difficult to
be assessed.
Implantation of a self-expanding valve has been related
to higher rates of atrioventricular blocks requiring a pace-
maker. This result is confirmed in the present study and may
be explained because of the different valve designs. The
self-expanding prosthesis has a stabilizing nitinol frame that
exerts greater radial forces on the left bundle branch, which
runs superficially just below the endocardium in the up-
permost part of the leftward ventricular septum.25 Tomaintain hemodynamic efficacy, the frame of the self-
expanding valve is dependent on its firm self-expansion to
avoid recoil and paravalvular regurgitation, and ongoing
compressive forces are needed to achieve greater prosthetic
stability. Although this complication does not affect prog-
nosis,8 it may increase costs and length of hospitalizations,
as the hazard of subsequent complications.26,27
Figure 3. Pooled analysis of risk of 30-day death (top) and stroke (bottom).
Figure 4. Pooled analysis of risk of moderate or severe aortic regurgitation at 30-day death (top) and pacemaker implantation (bottom).
Valvular Heart Disease/Basic Features of Included Studies 1723No differences for stroke were reported in the present
analysis with balloon-expandable devices. Catheter manip-
ulations of the calcified and diseased aortic valve may cause
embolization of aortic debris or thrombotic material result-
ing in stroke or TIA,28,29 but this does not appear to depend
on differences between self- or balloon-expandable devices.Thirty-day and 1-year death rates did not differ between
the 2 valves. Many explanations may be provided: although
higher rates of AR may exert a detrimental effect on prog-
nosis for patients treated with self-expanding devices,
follow-up is still limited (no >1 year) not allowing defini-
tive conclusions.
Figure 5. Pooled analysis of risk of major vascular complications (top) and life-threatening and major bleedings (bottom).
Figure 6. Pooled analysis of death at follow-up.
Figure 7. Meta-regression analysis for annulus diameter on aortic regurgi-
tation (beta 0.15; p <0.001).
1724 The American Journal of Cardiology (www.ajconline.org)The present analysis has many limitations. From a
methodologic point of view, we included both observational
studies, although adjusted with multivariate analysis, and
randomized controlled trials, consequently dealing with
different level of evidence. Moreover, from a clinical point
of view, in each study, AR was assessed through echocar-
diography, with the well-known limitations of this operator-
dependent assessment and without an independent corelaboratory assessing AR. Finally, in each study, outcomes
were reported with Valve Academic Research Consortium
(VARC) definition increasing reproducibility of these results.
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